$28.50
-0.94(-3.21%)
Mkt Cap $1.9B
$11.83
$29.45
52-Week Range
At a Glance
AI-generatedPharvaris advanced deucrictibant through pivotal Phase 3 trials and late-stage CMC scale-up in 2025, maintaining strategic focus on dual on-demand and prophylactic development paths while operating under the financial discipline of its 2021 Equity Incentive Plan and multi-CDMO supply framework.
6-K
Pharvaris reported €175.7 million full-year 2025 net loss and €291.7 million cash as of December 31, 2025, while advancing deucrictibant IR NDA submission in 1H2026 and anticipating CHAPTER-3 topline data in 3Q2026.$1.9B
Market Cap
—
Revenue
-$149M
Net Income
Employees108
Fundamentals
How The Business Makes Money
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Industry Biotechnology
Activity
Company Profile
CIK0001830487
ISINNL00150005Y4
CUSIPN69605108
Phone31 71 203 6410
AddressJ.H. Oortweg 21, Leiden, 2333 CH, NL
SEC EDGAR